search
Back to results

Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) (Hesperidin)

Primary Purpose

Covid19, Anosmia, Fever

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Hesperidin
Placebo
Sponsored by
Montreal Heart Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Covid19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Covid-19 positive by polymerase chain reaction (PCR) testing;
  • Participant must be able to evaluate their symptoms and report them in the symptoms diary;
  • Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials;
  • Males and females, at least 18 years of age, capable and willing to provide informed consent;
  • Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study;
  • Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms;
  • Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization);
  • Patient must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria:

  • Patient currently hospitalized or under immediate consideration for hospitalization;
  • Patient currently in shock or with hemodynamic instability;
  • Patient undergoing chemotherapy for cancer;
  • Patient is unable to take oral temperature using an electronic thermometer;
  • Patient who received at least one dose of the COVID-19 vaccine;
  • Female patient who is pregnant or breast-feeding or is considering becoming pregnant during the study;
  • People taking anticoagulant/antiplatelet medications, those with bleeding disorders, and people two weeks before or after surgery;
  • Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study;
  • Regular consumption of natural products containing more than 150 mg of hesperidin or regular consumption of more than 1 glass of orange juice per day;
  • Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin, microcrystalline cellulose, magnesium stearate.

Sites / Locations

  • Montreal Heart Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Hesperidin 1000mg

Placebo 1000mg

Arm Description

Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.

Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.

Outcomes

Primary Outcome Measures

Number of Subjects With COVID-19 Symptoms at Day 3.
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 3.
Number of Subjects With COVID-19 Symptoms at Day 7.
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 7.
Number of Subjects With COVID-19 Symptoms at Day 10.
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 10.
Number of Subjects With COVID-19 Symptoms at Day 14.
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 14.

Secondary Outcome Measures

Mean Number of COVID-19 Symptoms at Day 3.
Mean number of COVID-19 symptoms (range 0-13) at day 3.
Mean Number of COVID-19 Symptoms at Day 7.
Mean number of COVID-19 symptoms (range 0-13) at day 7.
Mean Number of COVID-19 Symptoms at Day 10.
Mean number of COVID-19 symptoms (range 0-13) at day 10.
Mean Number of COVID-19 Symptoms at Day 14.
Mean number of COVID-19 symptoms (range 0-13) at day 14.
Number of Subjects With Complete Disappearance of Any Symptom.
The descriptive statistics are the number of participants having complete disappearance of any symptom.
Number of Subjects With the Cough Symptom.
Number of subjects with the cough symptom at day 3.
Number of Subjects With the Cough Symptom.
Number of subjects with the cough symptom at day 7.
Number of Subjects With the Cough Symptom.
Number of subjects with the cough symptom at day 10.
Number of Subjects With the Cough Symptom.
Number of subjects with the cough symptom at day 14.
Number of Subjects With the Presence of Fever.
Number of subjects with the presence of fever (temperature > 38 degrees) at day 3.
Number of Subjects With the Presence of Fever.
Number of subjects with the presence of fever (temperature > 38 degrees) at day 7.
Number of Subjects With the Presence of Fever.
Number of subjects with the presence of fever (temperature > 38 degrees) at day 10.
Number of Subjects With the Presence of Fever.
Number of subjects with the presence of fever (temperature > 38 degrees) at day 14.
Number of Subjects With the Presence of Shortness of Breath.
Number of subjects with the presence of shortness of breath at day 3.
Number of Subjects With the Presence of Shortness of Breath.
Number of subjects with the presence of shortness of breath at day 7.
Number of Subjects With the Presence of Shortness of Breath.
Number of subjects with the presence of shortness of breath at day 10.
Number of Subjects With the Presence of Shortness of Breath.
Number of subjects with the presence of shortness of breath at day 14.
Number of Subjects With the Presence of Anosmia.
Number of subjects with the presence of anosmia at day 3.
Number of Subjects With the Presence of Anosmia.
Number of subjects with the presence of anosmia at day 7.
Number of Subjects With the Presence of Anosmia.
Number of subjects with the presence of anosmia at day 10.
Number of Subjects With the Presence of Anosmia.
Number of subjects with the presence of anosmia at day 14.
Number of Subjects With the Presence of Feverish or Chills.
Number of subjects with the presence of feverish or chills at day 3.
Number of Subjects With the Presence of Feverish or Chills.
Number of subjects with the presence of feverish or chills at day 7.
Number of Subjects With the Presence of Feverish or Chills.
Number of subjects with the presence of feverish or chills at day 10.
Number of Subjects With the Presence of Feverish or Chills.
Number of subjects with the presence of feverish or chills at day 14.
Number of Subjects With the Presence of Sore Throat.
Number of subjects with the presence of sore throat at day 3.
Number of Subjects With the Presence of Sore Throat.
Number of subjects with the presence of sore throat at day 7.
Number of Subjects With the Presence of Sore Throat.
Number of subjects with the presence of sore throat at day 10.
Number of Subjects With the Presence of Sore Throat.
Number of subjects with the presence of sore throat at day 14.
Number of Subjects With the Presence of Runny Nose.
Number of subjects with the presence of runny nose at day 3.
Number of Subjects With the Presence of Runny Nose.
Number of subjects with the presence of runny nose at day 7.
Number of Subjects With the Presence of Runny Nose.
Number of subjects with the presence of runny nose at day 10.
Number of Subjects With the Presence of Runny Nose.
Number of subjects with the presence of runny nose at day 14.
Number of Subjects With the Presence of Nausea/Vomiting.
Number of subjects with the presence of nausea/vomiting at day 3.
Number of Subjects With the Presence of Nausea/Vomiting.
Number of subjects with the presence of nausea/vomiting at day 7.
Number of Subjects With the Presence of Nausea/Vomiting.
Number of subjects with the presence of nausea/vomiting at day 10.
Number of Subjects With the Presence of Nausea/Vomiting.
Number of subjects with the presence of nausea/vomiting at day 14.
Number of Subjects With the Presence of Headache.
Number of subjects with the presence of headache at day 3.
Number of Subjects With the Presence of Headache.
Number of subjects with the presence of headache at day 7.
Number of Subjects With the Presence of Headache.
Number of subjects with the presence of headache at day 10.
Number of Subjects With the Presence of Headache.
Number of subjects with the presence of headache at day 14.
Number of Subjects With the Presence of General Weakness.
Number of subjects with the presence of general weakness at day 3.
Number of Subjects With the Presence of General Weakness.
Number of subjects with the presence of general weakness at day 7.
Number of Subjects With the Presence of General Weakness.
Number of subjects with the presence of general weakness at day 10.
Number of Subjects With the Presence of General Weakness.
Number of subjects with the presence of general weakness at day 14.
Number of Subjects With the Presence of Pain.
Number of subjects with the presence of pain at day 3.
Number of Subjects With the Presence of Pain.
Number of subjects with the presence of pain at day 7.
Number of Subjects With the Presence of Pain.
Number of subjects with the presence of pain at day 10.
Number of Subjects With the Presence of Pain.
Number of subjects with the presence of pain at day 14.
Number of Subjects With the Presence of Irritability/Confusion.
Number of subjects with the presence of irritability/confusion at day 3.
Number of Subjects With the Presence of Irritability/Confusion.
Number of subjects with the presence of irritability/confusion at day 7.
Number of Subjects With the Presence of Irritability/Confusion.
Number of subjects with the presence of irritability/confusion at day 10.
Number of Subjects With the Presence of Irritability/Confusion.
Number of subjects with the presence of irritability/confusion at day 14.
Number of Subjects With the Presence of Diarrhea.
Number of subjects with the presence of diarrhea at day 3.
Number of Subjects With the Presence of Diarrhea.
Number of subjects with the presence of diarrhea at day 7.
Number of Subjects With the Presence of Diarrhea.
Number of subjects with the presence of diarrhea at day 10.
Number of Subjects With the Presence of Diarrhea.
Number of subjects with the presence of diarrhea at day 14.

Full Information

First Posted
January 15, 2021
Last Updated
April 6, 2022
Sponsor
Montreal Heart Institute
Collaborators
Ingenew Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04715932
Brief Title
Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
Acronym
Hesperidin
Official Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
February 18, 2021 (Actual)
Primary Completion Date
May 25, 2021 (Actual)
Study Completion Date
June 7, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Montreal Heart Institute
Collaborators
Ingenew Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main aim of this study is to determine the effects of short-term treatment with hesperidin on COVID-19 symptoms in comparison with a placebo. Treatment effects will be observed through a symptoms diary that will be completed by participants throughout the study and by taking the oral temperature daily.
Detailed Description
This will be a randomized, double-blind, placebo-controlled study. The study will include subjects from Quebec diagnosed with COVID-19 infections. Following informed consent, 216 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either hesperidin 1000 mg once daily (q.d.)) or placebo (1:1 allocation ratio) for 14 days. Investigational drug will be delivered to the patients' homes with an electronic oral thermometer and a symptoms diary. Follow-up phone assessments will occur after 3, 7, 10, and 14 days following randomization for evaluation of COVID-19 symptoms. Electronic Case Report Form (eCRF) will be completed by the research personnel over the phone with the patients. The symptoms diary will be mailed back to the coordinating center at the end of the study in a pre-addressed envelope.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, Anosmia, Fever, Cough, Shortness of Breath, Sore Throat, Nausea, Vomiting, Headache, Muscle Weakness, Pain, Muscle, Pain, Chest, Pain, Joint, Pain, Abdominal, Pain, Irritable Mood, Confusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
216 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hesperidin 1000mg
Arm Type
Active Comparator
Arm Description
Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Arm Title
Placebo 1000mg
Arm Type
Placebo Comparator
Arm Description
Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Intervention Type
Drug
Intervention Name(s)
Hesperidin
Intervention Description
Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Patients will receive study medication Placebo and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Primary Outcome Measure Information:
Title
Number of Subjects With COVID-19 Symptoms at Day 3.
Description
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 3.
Time Frame
Day 3
Title
Number of Subjects With COVID-19 Symptoms at Day 7.
Description
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 7.
Time Frame
Day 7
Title
Number of Subjects With COVID-19 Symptoms at Day 10.
Description
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 10.
Time Frame
Day 10
Title
Number of Subjects With COVID-19 Symptoms at Day 14.
Description
Number of subjects with any of the following COVID-19 symptoms: fever (temperature > 38 degrees), cough, shortness of breath or anosmia, at day 14.
Time Frame
Day 14
Secondary Outcome Measure Information:
Title
Mean Number of COVID-19 Symptoms at Day 3.
Description
Mean number of COVID-19 symptoms (range 0-13) at day 3.
Time Frame
Day 3
Title
Mean Number of COVID-19 Symptoms at Day 7.
Description
Mean number of COVID-19 symptoms (range 0-13) at day 7.
Time Frame
Day 7
Title
Mean Number of COVID-19 Symptoms at Day 10.
Description
Mean number of COVID-19 symptoms (range 0-13) at day 10.
Time Frame
Day 10
Title
Mean Number of COVID-19 Symptoms at Day 14.
Description
Mean number of COVID-19 symptoms (range 0-13) at day 14.
Time Frame
Day 14
Title
Number of Subjects With Complete Disappearance of Any Symptom.
Description
The descriptive statistics are the number of participants having complete disappearance of any symptom.
Time Frame
From randomization to occurence of first event, assessed up to 14 days
Title
Number of Subjects With the Cough Symptom.
Description
Number of subjects with the cough symptom at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Cough Symptom.
Description
Number of subjects with the cough symptom at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Cough Symptom.
Description
Number of subjects with the cough symptom at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Cough Symptom.
Description
Number of subjects with the cough symptom at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Fever.
Description
Number of subjects with the presence of fever (temperature > 38 degrees) at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Fever.
Description
Number of subjects with the presence of fever (temperature > 38 degrees) at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Fever.
Description
Number of subjects with the presence of fever (temperature > 38 degrees) at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Fever.
Description
Number of subjects with the presence of fever (temperature > 38 degrees) at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Shortness of Breath.
Description
Number of subjects with the presence of shortness of breath at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Shortness of Breath.
Description
Number of subjects with the presence of shortness of breath at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Shortness of Breath.
Description
Number of subjects with the presence of shortness of breath at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Shortness of Breath.
Description
Number of subjects with the presence of shortness of breath at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Anosmia.
Description
Number of subjects with the presence of anosmia at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Anosmia.
Description
Number of subjects with the presence of anosmia at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Anosmia.
Description
Number of subjects with the presence of anosmia at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Anosmia.
Description
Number of subjects with the presence of anosmia at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Feverish or Chills.
Description
Number of subjects with the presence of feverish or chills at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Feverish or Chills.
Description
Number of subjects with the presence of feverish or chills at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Feverish or Chills.
Description
Number of subjects with the presence of feverish or chills at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Feverish or Chills.
Description
Number of subjects with the presence of feverish or chills at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Sore Throat.
Description
Number of subjects with the presence of sore throat at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Sore Throat.
Description
Number of subjects with the presence of sore throat at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Sore Throat.
Description
Number of subjects with the presence of sore throat at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Sore Throat.
Description
Number of subjects with the presence of sore throat at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Runny Nose.
Description
Number of subjects with the presence of runny nose at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Runny Nose.
Description
Number of subjects with the presence of runny nose at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Runny Nose.
Description
Number of subjects with the presence of runny nose at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Runny Nose.
Description
Number of subjects with the presence of runny nose at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Nausea/Vomiting.
Description
Number of subjects with the presence of nausea/vomiting at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Nausea/Vomiting.
Description
Number of subjects with the presence of nausea/vomiting at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Nausea/Vomiting.
Description
Number of subjects with the presence of nausea/vomiting at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Nausea/Vomiting.
Description
Number of subjects with the presence of nausea/vomiting at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Headache.
Description
Number of subjects with the presence of headache at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Headache.
Description
Number of subjects with the presence of headache at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Headache.
Description
Number of subjects with the presence of headache at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Headache.
Description
Number of subjects with the presence of headache at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of General Weakness.
Description
Number of subjects with the presence of general weakness at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of General Weakness.
Description
Number of subjects with the presence of general weakness at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of General Weakness.
Description
Number of subjects with the presence of general weakness at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of General Weakness.
Description
Number of subjects with the presence of general weakness at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Pain.
Description
Number of subjects with the presence of pain at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Pain.
Description
Number of subjects with the presence of pain at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Pain.
Description
Number of subjects with the presence of pain at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Pain.
Description
Number of subjects with the presence of pain at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Irritability/Confusion.
Description
Number of subjects with the presence of irritability/confusion at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Irritability/Confusion.
Description
Number of subjects with the presence of irritability/confusion at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Irritability/Confusion.
Description
Number of subjects with the presence of irritability/confusion at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Irritability/Confusion.
Description
Number of subjects with the presence of irritability/confusion at day 14.
Time Frame
Day 14
Title
Number of Subjects With the Presence of Diarrhea.
Description
Number of subjects with the presence of diarrhea at day 3.
Time Frame
Day 3
Title
Number of Subjects With the Presence of Diarrhea.
Description
Number of subjects with the presence of diarrhea at day 7.
Time Frame
Day 7
Title
Number of Subjects With the Presence of Diarrhea.
Description
Number of subjects with the presence of diarrhea at day 10.
Time Frame
Day 10
Title
Number of Subjects With the Presence of Diarrhea.
Description
Number of subjects with the presence of diarrhea at day 14.
Time Frame
Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Covid-19 positive by polymerase chain reaction (PCR) testing; Participant must be able to evaluate their symptoms and report them in the symptoms diary; Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials; Males and females, at least 18 years of age, capable and willing to provide informed consent; Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study; Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms; Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization); Patient must be able and willing to comply with the requirements of this study protocol. Exclusion Criteria: Patient currently hospitalized or under immediate consideration for hospitalization; Patient currently in shock or with hemodynamic instability; Patient undergoing chemotherapy for cancer; Patient is unable to take oral temperature using an electronic thermometer; Patient who received at least one dose of the COVID-19 vaccine; Female patient who is pregnant or breast-feeding or is considering becoming pregnant during the study; People taking anticoagulant/antiplatelet medications, those with bleeding disorders, and people two weeks before or after surgery; Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study; Regular consumption of natural products containing more than 150 mg of hesperidin or regular consumption of more than 1 glass of orange juice per day; Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin, microcrystalline cellulose, magnesium stearate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jocelyn Dupuis, MD
Organizational Affiliation
Montreal Heart Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montreal Heart Institute
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T1C8
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)

We'll reach out to this number within 24 hrs